Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)
Recursion Pharmaceuticals' (RXRX) quarterly Acquisitions came in at -$277.1 million in Q4 2024, down 390387.32% YoY from N/an in Q1 2024, and down 390387.32% on a QoQ basis from $71000.0 in Q4 2023.
Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 2 years of Acquisitions data on file, last reported at -$277.1 million in Q4 2024.
- Quarterly Acquisitions fell 390387.32% year-over-year to -$277.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$277.0 million (down 390287.32% YoY) and the FY2024 annual result came in at -$277.1 million, down 14927.33% from the prior year.
- Acquisitions declined to -$277.1 million in Q4 2024, from $71000.0 in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $71000.0 in Q4 2023 to a low of -$277.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -277.10 Mn |
| Dec 31, 2023 | 71,000.00 |